Springfusor versus standard of care in administration of magnesium sulphate

Randomized trial to compare Magnesium Sulphate administration for preeclampsia and eclampsia: Springfusor versus standard approach

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201712002887266

Enrollment

482

Registered

2017-12-18

Start date

2018-02-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy and Childbirth Preeclampsia, eclampsia

Interventions

Springfusor used in administration of magnesium sulphate

Standard of Care

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1.Pregnant women 20+ weeks of gestation or delivered within 24 hours, 2. diagnosed with preeclampsia and eclampsia i.e. have a raised blood pressure (systolic of >140 mmHg and diastolic > 90mmHg), proteinuria >1+. 3. Present within the study period 4. consent to participate in the study.

Exclusion criteria

Exclusion criteria: 1. Had received magnesium sulphate 24 hours prior to admission, 2) has known allergy to magnesium sulphate 3) elevated serum creatinine (>1.2 mg/dl).

Design outcomes

Primary

Measure	Time frame
¿Acceptability of Springfusor for administration of magnesium sulphate	—

Secondary

Measure	Time frame
rate of complications;Level of pain;Discontinuation	—

Countries

Uganda

Contacts

Public ContactSam Ononge

Senior lecturer

ononge2006@yahoo.com+256772486301

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026